` MBX (Microbix Biosystems Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

MBX
vs
S&P TSX Composite Index (Canada)

Over the past 12 months, MBX has underperformed S&P TSX Composite Index (Canada), delivering a return of -9% compared to the S&P TSX Composite Index (Canada)'s 23% growth.

Stocks Performance
MBX vs S&P TSX Composite Index (Canada)

Loading
MBX
S&P TSX Composite Index (Canada)
Add Stock

Performance Gap
MBX vs S&P TSX Composite Index (Canada)

Performance Gap Between MBX and GSPTSE
HIDDEN
Show

Performance By Year
MBX vs S&P TSX Composite Index (Canada)

Loading
MBX
S&P TSX Composite Index (Canada)
Add Stock

Competitors Performance
Microbix Biosystems Inc vs Peers

S&P TSX Composite Index (Canada)
MBX
ABBV
AMGN
GILD
VRTX
Add Stock

Microbix Biosystems Inc
Glance View

Market Cap
43.7m CAD
Industry
Biotechnology

Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm manufactures a range of biological materials for the diagnostics industry, notably antigens (Antigen business) used in immunoassays and its quality assessment and proficiency testing controls (QAPs business). The firm operates in two segments: the development, manufacturing, and sales of antigens as materials for the medical diagnostic industry or as quality assessment products (as finished products) and viral transport medium (VTM) and the development and commercialization of products or technologies such as Kinlytic and . The Kinlyti urokinase, which is a biologic thrombolytic drug used to treat blood clots. The firm's catalogue of catalogue covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually transmitted and insect-borne diseases. Its QAPs are available in over 30 countries.

MBX Intrinsic Value
HIDDEN
Show
Back to Top